Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Hoffmann

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|February 5, 2004
Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancerJens Hoffmann, Rolf Bohlmann, Nikolaus Heinrich, et al.
Frontiers in Oncology|April 28, 2023
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signaturesJoshua Alcaniz, Lars Winkler, Mathias Dahlmann, et al.
Plos Genetics|March 30, 2019
Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D culturesDirk Schumacher, Geoffroy Andrieux, Karsten Boehnke, et al.
Cancers|December 23, 2023
Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingDiana Behrens, Ulrike Pfohl, Theresia Conrad, et al.
Frontiers in Oncology|July 8, 2022
A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment StrategiesDennis Gürgen, Michael Becker, Mathias Dahlmann, et al.
European Journal of Neurology|November 7, 2024
Mobile stroke units services in Germany: A cost-effectiveness modeling perspective on catchment zones, operating modes, and staffingJohann S Rink, Kristina Szabo, Carolin Hoyer, et al.
Scientific Reports|August 23, 2017
Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domainDanielle M DiCara, Dimitri Y Chirgadze, Anthony R Pope, et al.
Molecular Cancer|October 21, 2021
Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D modelsMathias Dahlmann, Guido Gambara, Bernadette Brzezicha, et al.
International Journal of Cancer|December 7, 2020
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastomaBirte Arlt, Christin Zasada, Katharina Baum, et al.
Oncotarget|November 23, 2017
IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancerSonja M Kessler, Eva Lederer, Stephan Laggai, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|February 5, 2004
Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancerJens Hoffmann, Rolf Bohlmann, Nikolaus Heinrich, et al.
Frontiers in Oncology|April 28, 2023
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signaturesJoshua Alcaniz, Lars Winkler, Mathias Dahlmann, et al.
Plos Genetics|March 30, 2019
Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D culturesDirk Schumacher, Geoffroy Andrieux, Karsten Boehnke, et al.
Cancers|December 23, 2023
Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingDiana Behrens, Ulrike Pfohl, Theresia Conrad, et al.
Frontiers in Oncology|July 8, 2022
A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment StrategiesDennis Gürgen, Michael Becker, Mathias Dahlmann, et al.
European Journal of Neurology|November 7, 2024
Mobile stroke units services in Germany: A cost-effectiveness modeling perspective on catchment zones, operating modes, and staffingJohann S Rink, Kristina Szabo, Carolin Hoyer, et al.
Scientific Reports|August 23, 2017
Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domainDanielle M DiCara, Dimitri Y Chirgadze, Anthony R Pope, et al.
Molecular Cancer|October 21, 2021
Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D modelsMathias Dahlmann, Guido Gambara, Bernadette Brzezicha, et al.
International Journal of Cancer|December 7, 2020
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastomaBirte Arlt, Christin Zasada, Katharina Baum, et al.
Oncotarget|November 23, 2017
IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancerSonja M Kessler, Eva Lederer, Stephan Laggai, et al.
Pageof 9